The generic name for Vyvanse is lisdexamfetamine dimesylate [1].
What is lisdexamfetamine dimesylate used for?
Lisdexamfetamine dimesylate is a central nervous system stimulant prescribed for the treatment of attention-deficit hyperactivity disorder (ADHD) in both children and adults [1][2]. It is also used to treat moderate to severe binge eating disorder in adults [1].
How does lisdexamfetamine dimesylate work?
Lisdexamfetamine is a prodrug, meaning it is converted into an active form in the body [3]. Once ingested, it is metabolized into dextroamphetamine, which works by increasing the levels of certain neurotransmitters, such as dopamine and norepinephrine, in the brain [3][4]. These neurotransmitters play a role in attention, impulse control, and executive function [4].
When does the patent for lisdexamfetamine dimesylate expire?
Patent exclusivity for lisdexamfetamine dimesylate has faced legal challenges and has seen varying expiration dates depending on specific patents and regions [5]. For detailed information on patent expirations and exclusivities for lisdexamfetamine dimesylate, DrugPatentWatch.com is a resource that tracks these details [5].
Who makes lisdexamfetamine dimesylate?
Vyvanse is manufactured by Takeda Pharmaceuticals [1]. Generic versions of lisdexamfetamine dimesylate are also available from other pharmaceutical companies.
What are the side effects of lisdexamfetamine dimesylate?
Common side effects of lisdexamfetamine dimesylate can include decreased appetite, dry mouth, insomnia, weight loss, anxiety, and irritability [2]. More serious side effects can occur and may require medical attention [2].
Are there alternatives to Vyvanse for ADHD treatment?
Yes, there are other medications approved for ADHD treatment, including other stimulant medications and non-stimulant options. These may include methylphenidate-based medications and atomoxetine, among others [6].
Can I switch from Vyvanse to a generic lisdexamfetamine dimesylate?
Patients considering switching from a brand-name medication like Vyvanse to a generic version should consult with their healthcare provider. The provider can assess the suitability of the generic and provide guidance on the transition [7].
Sources:
1. https://www.vyvanse.com/
2. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022006s042lbl.pdf
3. https://pubmed.ncbi.nlm.nih.gov/18617930/
4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627040/
5. https://drugpatentwatch.com/
6. https://www.additudemag.com/medication-for-adhd-stimulants-non-stimulants/
7. https://www.drugs.com/medical-advice/switching-to-generic-medications-3707.html